Xenon Pharmaceuticals Inc. (XENE)
Nasdaq · Healthcare · Biotechnology
$37.57−1.18%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.6B
- 52-week range
- $36.07 – $72.66
- 52-week change
- −3.87%
- EPS (trailing)
- −$4.74
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $7.5M
- Net income
- −$346M
- Operating margin
- −4974.3%
- Diluted EPS
- −$4.36
- Free cash flow
- −$280M
From the company’s annual report on SEC EDGAR.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Headquarters: Burnaby, Canada · 358 employees · xenon-pharma.com